Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer ...
A single-patient report from China shows that PSMA and FDG PET scans, stable blood markers and biopsy each told different ...
KIMS Hospitals in Hyderabad has introduced Tulsa-Pro, an advanced prostate cancer treatment system developed by Canada's Profound Medical Corp.
As part of Prostate Cancer Awareness Month, a physician from the University Medical Center of El Paso is encouraging men to ...
Posters presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid examined how genomic testing ...
WTVF News Channel 5 ’s “Morningline” program interviewed Denise Garcia, MD, Assistant Professor of Surgery, about new ...
Prostate cancer is the most common cancer in men – in 2013, it affected more than one million men across the world.The cancer does not behave the same ...
On Friday, Veracyte, Inc. ( VCYT) announced new data showing that its Decipher Prostate Genomic Classifier can help identify men with very high-risk, nonmetastatic prostate cancer who may benefit from ...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
Actinium Pharmaceuticals ( ATNM) announced that its first-in-human Phase 1 study of ATNM-400, an investigational HER3-targeted radiotherapy, will be featured at the ESMO 2026 Congress in Madrid, Spain ...
New research shows that inhibiting the ERG protein, overproduced in about half of prostate cancers, selectively impairs DNA ...
Actinium Pharmaceuticals begins Phase 1 trial for ATNM-400, a HER3 targeted radiotherapy, in advanced prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results